FDA Declines Approval of New Smoking Cessation Drug Cytisinicline, Citing Manufacturing Deficiencies

WASHINGTON — The U.S. Food and Drug Administration (FDA) has declined to approve cytisinicline, an investigational non-nicotine drug designed to help adults quit smoking, delaying the market entry of a highly anticipated prescription treatment option. According to an announcement from the drug’s developer, Achieve Life Sciences, the regulatory agency’s decision was based strictly on unresolved third-party manufacturing and product labeling issues rather than concerns over the medication’s clinical efficacy or safety.

The agency issued a Complete Response Letter (CRL) on June 22, 2026, marking a temporary setback for public health efforts. The decision stalls what could have been the first new prescription smoking-cessation pharmacotherapy approved in the United States in nearly two decades. With approximately 25 million American adults still smoking combustible cigarettes, public health officials have expressed a continuous need for diversified cessation tools. Achieve Life Sciences reported that it has already transitioned its commercial manufacturing operations to a new domestic partner and plans to resubmit its New Drug Application (NDA) by the fourth quarter of 2026, aiming for a potential approval in the first half of 2027.

Technical Hurdles Clear Path for U.S. Manufacturing Overhaul

The FDA’s regulatory rejection focused entirely on procedural and administrative obstacles. The CRL cited outstanding manufacturing observations from a current Good Manufacturing Practice (cGMP) inspection at a previous third-party manufacturing facility. This site had received an “Official Action Indicated” classification for general facility issues completely unrelated to the production of cytisinicline itself. Additionally, the FDA noted that final product labeling guidelines could not be mutually finalized prior to the agency’s statutory action deadline.

Crucially, the FDA did not request any new clinical trials or identify deficiencies in how the drug works or its overall safety profile. Anticipating these manufacturing complications, Achieve Life Sciences had already initiated a transition of its primary commercial production pipeline to Adare Pharma Solutions, a contract manufacturer based in the United States.

“The FDA’s feedback provides a clear and actionable path forward,” stated Andrew D. Goldberg, MD, Chief Executive Officer of Achieve Life Sciences, in a corporate press release. “Our clinical data stands on its own: two successful Phase 3 trials and a robust open-label safety study. As we work with the FDA to resolve these remaining requirements, we are simultaneously advancing our commercial readiness for launch.”

How Cytisinicline Targets Nicotine Addiction

Cytisinicline is a plant-derived alkaloid structurally similar to nicotine. It acts as a selective partial agonist at alpha-4-beta-2 ($\alpha_4\beta_2$) nicotinic acetylcholine receptors in the brain.

[Cytisinicline Action in the Brain]
   │
   ├─► Binds partially to Nicotine Receptors ──► Mitigates Cravings & Withdrawal
   │
   └─► Blocks Nicotine Binding ────────────────► Reduces Smoking Satisfaction

By partially stimulating these receptors, cytisinicline releases small amounts of dopamine, which helps suppress severe withdrawal symptoms and the intense cravings associated with quitting. Simultaneously, it blocks inhaled nicotine from binding to those same receptors, rendering a slip-up or a cigarette far less physically satisfying.

Unlike conventional over-the-counter nicotine replacement therapies (NRTs)—such as nicotine patches, gums, and lozenges—cytisinicline is entirely nicotine-free. This mechanism makes it a uniquely appealing prescription alternative for individuals seeking to sever their physical dependence on nicotine altogether rather than tapering down using the substance itself.

Robust Clinical Evidence Backs Efficacy

The clinical backbone supporting the drug’s regulatory package stems from major late-stage testing, most notably the pivotal Phase 3 ORCA-3 randomized clinical trial published in JAMA Internal Medicine. The multicenter study evaluated 792 adult smokers who consumed an average of 10 or more cigarettes daily and had failed at least one previous quit attempt.

Participants were randomly assigned to one of three groups: a 6-week course of 3 mg cytisinicline taken three times daily, a 12-week course of the same regimen, or a matching placebo. Crucially, all three groups received standardized, brief behavioral counseling to reflect optimal cessation protocols.

Continuous Abstinence Rates (ORCA-3 Trial)

Beyond biochemically verified abstinence, researchers found that cytisinicline significantly diminished self-reported nicotine craving scores compared to the placebo group starting as early as week two. The drug also demonstrated an encouraging tolerability profile. Data across the clinical development program, which encompasses safety evaluations of more than 1,500 participants, revealed no treatment-related serious adverse events. The most frequent side effects reported were minor, including insomnia, abnormal dreams, nausea, and mild headaches.

The Public Health Context: Why More Options Matter

According to the Centers for Disease Control and Prevention (CDC), tobacco use remains the leading cause of preventable disease, disability, and death in the United States, driving nearly 500,000 deaths annually. While the CDC notes that existing FDA-approved cessation medications can double a person’s chances of successfully quitting, long-term success rates remain modest. The medical community currently utilizes seven FDA-approved first-line medications: five forms of nicotine replacement therapy, alongside two oral non-nicotine pills—bupropion and varenicline.

“Nicotine dependence is a complex, chronic relapsing medical condition,” explained Dr. Elena Vance, a preventative medicine specialist and tobacco cessation consultant who was not involved in the cytisinicline trials. “Most patients require multiple attempts to quit permanently. Because individual responses, side-effect profiles, and underlying health factors vary wildly, clinicians desperately need an expanded therapeutic toolbox to tailor strategies effectively.”

Independent evaluations have also highlighted the drug’s clinical promise. A comprehensive evidence report published by the Institute for Clinical and Economic Review (ICER) concluded that cytisinicline exhibits a net health benefit at least equivalent to, and potentially better than, varenicline. The independent review panel noted that cytisinicline achieved comparable quit rates while generating significantly fewer gastrointestinal complaints, which frequently cause patients to abandon varenicline therapy prematurely.

Study Limitations and Real-World Nuances

Despite the strong clinical performance outlined in the ORCA-3 trial, public health experts point out certain nuances that could affect the medication’s real-world utility.

• Intensive Behavioral Scaffolding: Trial participants received regular behavioral counseling sessions. In routine clinical care, many individuals attempt to use cessation medications without concurrent counseling, which could result in lower real-world quit rates than those observed in controlled research environments.

• Demographic Diversity Gaps: The participant cohort in the ORCA-3 trial exhibited limited racial and ethnic diversity, with approximately 80% identifying as White. This dynamic restricts the immediate generalizability of the findings across broader socio-demographic populations heavily impacted by tobacco disparities.

• Rigid Dosing Schedule: Cytisinicline’s pharmacological half-life is roughly 4.8 hours, notably shorter than varenicline’s 17-hour half-life. Consequently, patients must adhere to a three-times-daily dosing schedule, which may present compliance challenges compared to simpler once- or twice-daily therapies.

Immediate Guidance for Consumers

For individuals currently attempting to overcome tobacco dependence, the immediate takeaway is clear: while cytisinicline represents a promising development, it remains an unapproved, investigational compound that cannot yet be prescribed.

Public health officials emphasize that smokers should not delay their health goals in anticipation of new drug entries. Highly effective, established medical therapies and behavioral frameworks are available today. Individuals motivated to quit are encouraged to speak with their primary care physicians or utilize state health quitlines (such as 1-800-QUIT-NOW) to construct a structured, evidence-based cessation strategy combining counseling with currently available FDA-approved medications.

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://www.reuters.com/legal/litigation/us-fda-declines-approve-achieve-life-sciences-smoking-cessation-drug-2026-06-22/